GlassScriptPhysician profile
Sandra Anne Kopp
NPI 1447552948
$8,635.45
in general payments reported to CMS, 2019-2025
43 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $37.40 · 2021: $653 · 2022: $2,361 · 2023: $1,392 · 2024: $2,256 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,398 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,397.66 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $1,666.39 | 2019-2022 | |
| Abbvie INC. | $863.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $732.08 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $665.10 | 2020-2025 | Winlevi, Ilumya |
| Merz North America, INC. | $510.73 | 2021 | |
| Lilly USA, LLC | $442.81 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $392.65 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $341.41 | 2022-2025 | |
| Leo Pharma INC. | $325.91 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $302.94 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $278.59 | 2021-2025 | |
| Pfizer INC. | $213.75 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $205.62 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $194.90 | 2022-2025 | Tremfya |
| Ucb, INC. | $181.42 | 2021-2025 | Bimzelx |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $173.16 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Botanix Sb INC | $149.29 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $124.10 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $102.79 | 2023-2024 | Vtama |
| Biofrontera INC. | $93.81 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.06 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Journey Medical Corporation | $78.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $58.68 | 2021-2025 | Libtayo |
| Kerecis Limited | $56.79 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Sensus Healthcare, INC. | $51.47 | 2024 | |
| Revance Therapeutics, INC. | $43.43 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.46 | 2024 | Spevigo |
| Celgene Corporation | $29.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.14 | 2023 | Saphnelo |
| Springworks Therapeutics, INC. | $20.07 | 2025 | Gomekli |
| Mimedx Group, INC. | $18.18 | 2024 | |
| Genentech USA, INC. | $17.12 | 2023 | Xolair |
| Allergan, INC. | $16.93 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.74 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $15.22 | 2024 | Xtrac |
| Blueprint Medicines Corporation | $15.08 | 2024 | Ayvakit |
| Paratek Pharmaceuticals, INC. | $14.78 | 2022 | |
| Kyowa Kirin, INC. | $14.67 | 2024 | Poteligeo |
| Almirall LLC | $14.20 | 2021 | |
| Lnhc, INC | $13.84 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $13.84 | 2023 | Seglentis |
| Vyne Pharmaceuticals INC. | $13.62 | 2020 | |
| Organon LLC | $5.70 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.